BARDA will support the enrollment for a Phase 3 clinical trial to evaluate the use of an antibacterial drug combination, cefepime-taniborbactam, being developed by Venatorx Pharmaceuticals, Inc., of Malvern, Pennsylvania, USA to treat patients with hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP).
HABP/VABP represents a common infection caused by gram-negative bacteria and is a major cause of death, morbidity, and resource utilization in hospitalized patients globally. Multidrug-resistant (MDR) VABP accounts for 3 to 17 percent of intensive care unit deaths. With the increase in MDR gram-negative bacteria, prescribing an effective antibiotic for the treatment of HABP/VABP is a challenge to healthcare providers.
Venatorx’s product includes a novel compound, taniborbactam, which when combined with cefepime, a currently marketed cephalosporin antibiotic, may overcome certain forms of antibiotic resistance. Cefepime-taniborbactam holds potential as an intravenous treatment for some drug-resistant bacteria not susceptible to currently available antibiotics, including gram-negative infections that cause HABP/VABP and complicated urinary tract infections (cUTI), as well as infections caused by potential bioterrorism pathogens.
Antibiotic-resistant infections are a growing health security concern and are often costly to treat, which means that novel drugs and technologies to treat them could be pivotal in patient care. Healthcare providers need readily deployable therapeutics to combat bacterial infections.
BARDA and Venatorx will share the costs of the HABP/VABP clinical trial including site activation, patient enrollment, and completion.
This award is one component of the BARDA’s Chemical, Biological, Radiological, and Nuclear (CBRN) Division medical countermeasure portfolio; visit the CBRN Portfolio to learn more.
About Venatorx Pharmaceuticals, Inc.:
The following information is provided by the company and does not indicate endorsement by the federal government of the company or its products.
Venatorx is a private, clinical-stage pharmaceutical company focused on improving health outcomes for patients with multi-drug-resistant bacterial infections and hard-to-treat viral infections. More information is available at www.venatorx.com